nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—vaginal cancer	0.901	1	CtDrD
Erlotinib—HIPK4—female reproductive system—vaginal cancer	0.00203	0.0204	CbGeAlD
Erlotinib—LTK—female reproductive system—vaginal cancer	0.002	0.0202	CbGeAlD
Erlotinib—TNK1—uterine cervix—vaginal cancer	0.00196	0.0198	CbGeAlD
Erlotinib—TNK1—urethra—vaginal cancer	0.0018	0.0182	CbGeAlD
Erlotinib—TNK1—endometrium—vaginal cancer	0.00177	0.0179	CbGeAlD
Erlotinib—AURKC—female reproductive system—vaginal cancer	0.00173	0.0174	CbGeAlD
Erlotinib—TNK1—mammalian vulva—vaginal cancer	0.00172	0.0173	CbGeAlD
Erlotinib—TNK1—uterus—vaginal cancer	0.00164	0.0165	CbGeAlD
Erlotinib—EPHA6—female reproductive system—vaginal cancer	0.0016	0.0161	CbGeAlD
Erlotinib—JAK3—female reproductive system—vaginal cancer	0.0016	0.0161	CbGeAlD
Erlotinib—EGFR—uterine cervix—vaginal cancer	0.00157	0.0158	CbGeAlD
Erlotinib—PIP4K2C—uterine cervix—vaginal cancer	0.00152	0.0153	CbGeAlD
Erlotinib—JAK3—female gonad—vaginal cancer	0.00146	0.0147	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—vaginal cancer	0.00146	0.0147	CbGeAlD
Erlotinib—ULK3—uterine cervix—vaginal cancer	0.00145	0.0146	CbGeAlD
Erlotinib—PIP4K2C—urethra—vaginal cancer	0.0014	0.0141	CbGeAlD
Erlotinib—PIP4K2C—endometrium—vaginal cancer	0.00138	0.0139	CbGeAlD
Erlotinib—EGFR—mammalian vulva—vaginal cancer	0.00137	0.0138	CbGeAlD
Erlotinib—MKNK1—uterine cervix—vaginal cancer	0.00137	0.0138	CbGeAlD
Erlotinib—TNK1—female gonad—vaginal cancer	0.00134	0.0135	CbGeAlD
Erlotinib—ULK3—urethra—vaginal cancer	0.00134	0.0135	CbGeAlD
Erlotinib—PIP4K2C—mammalian vulva—vaginal cancer	0.00133	0.0134	CbGeAlD
Erlotinib—TNK1—vagina—vaginal cancer	0.00133	0.0134	CbGeAlD
Erlotinib—ULK3—endometrium—vaginal cancer	0.00132	0.0132	CbGeAlD
Erlotinib—EGFR—uterus—vaginal cancer	0.00131	0.0132	CbGeAlD
Erlotinib—SLK—uterine cervix—vaginal cancer	0.0013	0.013	CbGeAlD
Erlotinib—ULK3—mammalian vulva—vaginal cancer	0.00127	0.0128	CbGeAlD
Erlotinib—FLT3—female reproductive system—vaginal cancer	0.00126	0.0127	CbGeAlD
Erlotinib—MKNK1—urethra—vaginal cancer	0.00126	0.0127	CbGeAlD
Erlotinib—MKNK1—endometrium—vaginal cancer	0.00124	0.0125	CbGeAlD
Erlotinib—ULK3—uterus—vaginal cancer	0.00121	0.0122	CbGeAlD
Erlotinib—MKNK1—mammalian vulva—vaginal cancer	0.0012	0.0121	CbGeAlD
Erlotinib—SLK—urethra—vaginal cancer	0.00119	0.012	CbGeAlD
Erlotinib—SLK—endometrium—vaginal cancer	0.00117	0.0118	CbGeAlD
Erlotinib—FLT3—female gonad—vaginal cancer	0.00115	0.0116	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—vaginal cancer	0.00114	0.0115	CbGeAlD
Erlotinib—SLK—mammalian vulva—vaginal cancer	0.00113	0.0114	CbGeAlD
Erlotinib—STK10—uterine cervix—vaginal cancer	0.00113	0.0113	CbGeAlD
Erlotinib—ABL2—female gonad—vaginal cancer	0.0011	0.011	CbGeAlD
Erlotinib—ABL2—vagina—vaginal cancer	0.00109	0.011	CbGeAlD
Erlotinib—ULK3—female reproductive system—vaginal cancer	0.00109	0.011	CbGeAlD
Erlotinib—SLK—uterus—vaginal cancer	0.00108	0.0109	CbGeAlD
Erlotinib—EGFR—female gonad—vaginal cancer	0.00107	0.0108	CbGeAlD
Erlotinib—PIP4K2C—female gonad—vaginal cancer	0.00104	0.0105	CbGeAlD
Erlotinib—PIP4K2C—vagina—vaginal cancer	0.00103	0.0104	CbGeAlD
Erlotinib—MKNK1—female reproductive system—vaginal cancer	0.00103	0.0103	CbGeAlD
Erlotinib—MAP2K5—uterine cervix—vaginal cancer	0.00101	0.0101	CbGeAlD
Erlotinib—ULK3—female gonad—vaginal cancer	0.000991	0.00998	CbGeAlD
Erlotinib—STK10—mammalian vulva—vaginal cancer	0.000986	0.00993	CbGeAlD
Erlotinib—ULK3—vagina—vaginal cancer	0.000985	0.00992	CbGeAlD
Erlotinib—STK10—uterus—vaginal cancer	0.000939	0.00946	CbGeAlD
Erlotinib—MKNK1—female gonad—vaginal cancer	0.000933	0.00939	CbGeAlD
Erlotinib—MKNK1—vagina—vaginal cancer	0.000927	0.00934	CbGeAlD
Erlotinib—MAP2K5—urethra—vaginal cancer	0.000925	0.00931	CbGeAlD
Erlotinib—MAP2K5—endometrium—vaginal cancer	0.00091	0.00916	CbGeAlD
Erlotinib—SLK—female gonad—vaginal cancer	0.000884	0.0089	CbGeAlD
Erlotinib—MAP2K5—mammalian vulva—vaginal cancer	0.000881	0.00886	CbGeAlD
Erlotinib—SLK—vagina—vaginal cancer	0.000878	0.00884	CbGeAlD
Erlotinib—STK10—female reproductive system—vaginal cancer	0.000844	0.0085	CbGeAlD
Erlotinib—ABL1—uterine cervix—vaginal cancer	0.000776	0.00782	CbGeAlD
Erlotinib—STK10—female gonad—vaginal cancer	0.000768	0.00773	CbGeAlD
Erlotinib—STK10—vagina—vaginal cancer	0.000764	0.00769	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—vaginal cancer	0.000754	0.00759	CbGeAlD
Erlotinib—ORM1—endometrium—vaginal cancer	0.000739	0.00744	CbGeAlD
Erlotinib—ABL1—urethra—vaginal cancer	0.000714	0.00718	CbGeAlD
Erlotinib—ABL1—endometrium—vaginal cancer	0.000702	0.00707	CbGeAlD
Erlotinib—MAP2K5—female gonad—vaginal cancer	0.000686	0.00691	CbGeAlD
Erlotinib—MAP2K5—vagina—vaginal cancer	0.000682	0.00687	CbGeAlD
Erlotinib—ABL1—mammalian vulva—vaginal cancer	0.000679	0.00684	CbGeAlD
Erlotinib—SLCO2B1—uterus—vaginal cancer	0.000653	0.00657	CbGeAlD
Erlotinib—ABL1—uterus—vaginal cancer	0.000647	0.00651	CbGeAlD
Erlotinib—ORM1—female reproductive system—vaginal cancer	0.000612	0.00616	CbGeAlD
Erlotinib—SLCO2B1—female reproductive system—vaginal cancer	0.000587	0.00591	CbGeAlD
Erlotinib—ABL1—female reproductive system—vaginal cancer	0.000582	0.00586	CbGeAlD
Erlotinib—CYP1B1—uterus—vaginal cancer	0.000548	0.00552	CbGeAlD
Erlotinib—SLCO2B1—female gonad—vaginal cancer	0.000534	0.00538	CbGeAlD
Erlotinib—ABL1—female gonad—vaginal cancer	0.000529	0.00533	CbGeAlD
Erlotinib—ABL1—vagina—vaginal cancer	0.000526	0.0053	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—vaginal cancer	0.000493	0.00496	CbGeAlD
Erlotinib—ABCG2—uterine cervix—vaginal cancer	0.00049	0.00493	CbGeAlD
Erlotinib—CYP1A1—epithelium—vaginal cancer	0.000469	0.00472	CbGeAlD
Erlotinib—CYP1A1—uterine cervix—vaginal cancer	0.000465	0.00468	CbGeAlD
Erlotinib—CYP2C8—endometrium—vaginal cancer	0.000455	0.00458	CbGeAlD
Erlotinib—CYP3A5—uterine cervix—vaginal cancer	0.000454	0.00458	CbGeAlD
Erlotinib—ABCG2—urethra—vaginal cancer	0.00045	0.00453	CbGeAlD
Erlotinib—CYP1B1—female gonad—vaginal cancer	0.000448	0.00451	CbGeAlD
Erlotinib—ABCG2—endometrium—vaginal cancer	0.000443	0.00446	CbGeAlD
Erlotinib—ABCG2—mammalian vulva—vaginal cancer	0.000428	0.00431	CbGeAlD
Erlotinib—CYP1A1—urethra—vaginal cancer	0.000427	0.0043	CbGeAlD
Erlotinib—ABCG2—uterus—vaginal cancer	0.000408	0.00411	CbGeAlD
Erlotinib—CYP1A1—mammalian vulva—vaginal cancer	0.000407	0.00409	CbGeAlD
Erlotinib—CYP1A1—uterus—vaginal cancer	0.000387	0.0039	CbGeAlD
Erlotinib—CYP2C8—female reproductive system—vaginal cancer	0.000377	0.0038	CbGeAlD
Erlotinib—CYP1A1—female reproductive system—vaginal cancer	0.000348	0.00351	CbGeAlD
Erlotinib—CYP2C8—vagina—vaginal cancer	0.000341	0.00344	CbGeAlD
Erlotinib—ABCG2—female gonad—vaginal cancer	0.000334	0.00336	CbGeAlD
Erlotinib—ABCG2—vagina—vaginal cancer	0.000332	0.00334	CbGeAlD
Erlotinib—CYP1A1—female gonad—vaginal cancer	0.000317	0.00319	CbGeAlD
Erlotinib—CYP1A1—vagina—vaginal cancer	0.000315	0.00317	CbGeAlD
Erlotinib—CYP3A5—female gonad—vaginal cancer	0.00031	0.00312	CbGeAlD
Erlotinib—CYP3A5—vagina—vaginal cancer	0.000308	0.0031	CbGeAlD
Erlotinib—CYP3A4—female reproductive system—vaginal cancer	0.000256	0.00257	CbGeAlD
Erlotinib—CYP2D6—female reproductive system—vaginal cancer	0.000251	0.00253	CbGeAlD
Erlotinib—ABCB1—epithelium—vaginal cancer	0.000244	0.00245	CbGeAlD
Erlotinib—ABCB1—uterine cervix—vaginal cancer	0.000241	0.00243	CbGeAlD
Erlotinib—CYP2D6—female gonad—vaginal cancer	0.000229	0.0023	CbGeAlD
Erlotinib—ABCB1—urethra—vaginal cancer	0.000222	0.00223	CbGeAlD
Erlotinib—ABCB1—endometrium—vaginal cancer	0.000218	0.0022	CbGeAlD
Erlotinib—ABCB1—mammalian vulva—vaginal cancer	0.000211	0.00213	CbGeAlD
Erlotinib—ABCB1—uterus—vaginal cancer	0.000201	0.00203	CbGeAlD
Erlotinib—ABCB1—female reproductive system—vaginal cancer	0.000181	0.00182	CbGeAlD
Erlotinib—ABCB1—female gonad—vaginal cancer	0.000165	0.00166	CbGeAlD
Erlotinib—ABCB1—vagina—vaginal cancer	0.000164	0.00165	CbGeAlD
